Skip to main content

Lead Poisoning

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Magellan
MagellanWALLACE, ID
1 program
Lead testingN/A1 trial
Active Trials
NCT03256383Unknown190Est. Aug 2017
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
succimerN/A1 trial
Active Trials
NCT00004838Completed175Est. Jul 1998

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MagellanLead testing
Human BioSciencessuccimer

Clinical Trials (2)

Total enrollment: 365 patients across 2 trials

Plan for Testing Fingerstick Bloods on Magellan Systems

Start: Jul 2017Est. completion: Aug 2017190 patients
N/AUnknown

Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children

Start: Sep 1997Est. completion: Jul 1998175 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.